Skip to main content

Patient Search

Testimonials Testimonials

Displaying 1 - 6 of 6

A Phase II / III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma

Melanoma

This phase II / III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Melanoma
II/III
Johnson, Douglas
NCT02339571
ECOGMELEA6141

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Melanoma

A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibitor.
Melanoma
II
Johnson, Douglas
NCT04577807
VICCMEL20109

Storage and Research Use of Human Biospecimens from Melanoma Patients and Clinical Testing for the Assignment of Therapy

Melanoma

Melanoma
N/A
Johnson, Douglas
NCT01205815
VICCMEL09109

Wren Melanoma Study

Melanoma

Melanoma
N/A
Kauffmann, Rondi
NCT03267381
VICCMEL1783

Melanoma, Pigmented Lesion and Cutaneous Malignancy Tissue and Bio-Specimen Repository

Multiple Cancer Types

Dermatologic, Melanoma
N/A
Kauffmann, Rondi
VICCMEL0287

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Multiple Cancer Types

ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a monotherapy or in combination with other anticancer agents.
Breast, Colon, Lung, Melanoma, Non Small Cell, Ovarian, Phase I, Rectal
I
Berlin, Jordan
NCT04244552
VICCPHI2040